Triple agonist UBT251 showed a mean HbA1c reduction of up to 2.16% after 24 weeks in phase 2 trial in Chinese patients with type 2 diabetes Media Outreach|25/03/2026oleh RRINEWSS UBT251 is a triple agonist of the receptors for GLP-1, GIP and
Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China Media Outreach|24/02/2026oleh RRINEWSS UBT251 is a triple agonist of the receptors for GLP-1, GIP and
